A pilot study of nimotuzumab plus single agent chemotherapy as second- or third-line treatment or more in patients with recurrent, persistent or metastatic cervical cancer.
Cancer Biol Ther
; 16(5): 684-9, 2015.
Article
em En
| MEDLINE
| ID: mdl-25802932
Palavras-chave
ALT, Alanine Aminotransferase; AST, Aspartate Aminotransferase; CTCAE, Common Terminology Criteria for Adverse Events; ECOG, Eastern Cooperative Oncology Group; EGFR; EGFR, Epidermal Growth Factor Receptor; G-CSF, Granulocyte-Colony Stimulating Factor; RECIST, Response and Evaluation Criteria In Solid Tumors; advanced cervical cancer; monoclonal antibody; nimotuzumab; pilot study
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias do Colo do Útero
/
Anticorpos Monoclonais Humanizados
Tipo de estudo:
Prognostic_studies
Limite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2015
Tipo de documento:
Article